Tackling Strong Biofilm and Multi-virulent Vancomycin-resistant Via Natural Alkaloid-based Porous Nanoparticles: Perspective Towards Near Future Eradication
Overview
Infectious Diseases
Microbiology
Authors
Affiliations
Introduction: As a growing direction, nano-based therapy has become a successful paradigm used to address the phytogenic delivery-related problems in overcoming multivirulent vancomycin-resistant (VRSA) infection.
Methods: Hence, our aim was to develop and assess a novel nanocarrier system (mesoporous silica nanoparticles, MPS-NPs) for free berberine (Free-BR) as an antimicrobial alkaloid against strong biofilm-producing and multi-virulent VRSA strains using and mouse model.
Results And Discussion: Our outcomes demonstrated vancomycin resistance in 13.7% of () strains categorized as VRSA. Notably, strong biofilm formation was observed in 69.2% of VRSA strains that were all positive for gene. All strong biofilm-producing VRSA strains harbored a minimum of two virulence genes comprising and with 44.4% of them possessing all five virulence genes (, , , , and ), and 88.9% being multi-virulent. The study findings affirmed excellent antimicrobial and antibiofilm properties of BR-loaded MPS-NPs. Real-time quantitative reverse transcription PCR (qRT-PCR) assay displayed the downregulating role of BR-loaded MPS-NPs on strong biofilm-producing and multi-virulent VRSA strains virulence and genes in both and mice models. Additionally, BR-loaded MPS-NPs supplementation has a promising role in attenuating the upregulated expression of pro-inflammatory cytokines' genes in VRSA-infected mice with attenuation in pro-apoptotic genes expression resulting in reduced VRSA-induced apoptosis. In essence, the current study recommends the future scope of using BR-loaded MPS-NPs as auspicious alternatives for antimicrobials with tremendous antimicrobial, antibiofilm, anti-quorum sensing (QS), and anti-virulence effectiveness against problematic strong biofilm-producing and multi-virulent VRSA-associated infections.
in Inflammation and Pain: Update on Pathologic Mechanisms.
Rasquel-Oliveira F, Ribeiro J, Martelossi-Cebinelli G, Costa F, Nakazato G, Casagrande R Pathogens. 2025; 14(2).
PMID: 40005560 PMC: 11858194. DOI: 10.3390/pathogens14020185.
Nanotechnology Meets Phytotherapy: A Cutting-Edge Approach to Treat Bacterial Infections.
Pacyga K, Pacyga P, Szuba E, Viscardi S, Topola E, Duda-Madej A Int J Mol Sci. 2025; 26(3).
PMID: 39941020 PMC: 11818366. DOI: 10.3390/ijms26031254.
Al-Nasser A, El-Demerdash A, Ibrahim D, Abd El-Hamid M, Al-Khalaifah H, El-Borady O Front Vet Sci. 2024; 11:1474942.
PMID: 39575436 PMC: 11578965. DOI: 10.3389/fvets.2024.1474942.
Rahmanian N, Moulavi P, Ashrafi F, Sharifi A, Asadi S BMC Microbiol. 2024; 24(1):462.
PMID: 39516717 PMC: 11546402. DOI: 10.1186/s12866-024-03615-8.
Targeting bacterial biofilm-related genes with nanoparticle-based strategies.
Afrasiabi S, Partoazar A Front Microbiol. 2024; 15:1387114.
PMID: 38841057 PMC: 11150612. DOI: 10.3389/fmicb.2024.1387114.